Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26321498 | 0.84 | ADORA2B (0.37) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL22868408 | 0.82 | ADORA2B (0.40) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL892211 | 0.79 | MEN1 (0.47) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL9955714 | 0.78 | ADORA2B (0.36) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL9957793 | 0.78 | CA12 (0.34) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL892436 | 0.78 | MEN1 (0.46) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL2452822 | 0.78 | MEN1 (0.59) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL25434536 | 0.75 | MEN1 (0.43) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL9957507 | 0.75 | ADORA2B (0.34) | ADORA2BGLABLMADORA3MEN1 | |
| SCHEMBL10147007 | 0.75 | ADORA2B (0.34) | ADORA2BGLABLMADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129083-A1 | IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2023150569-A1 | IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150569-A1 | IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | disclosed |
| US-20210315886-A1 | IMIDAZOTETRAZINE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210002286-A1 | IMIDAZOTETRAZINE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2020033880-A1 | IMIDAZOTETRAZINE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | MCL1, IDH1, IDH2 | ADORA2B 3556/4885GLA 470/4885BLM 2834/4885 |
| US-20250129083-A1 | IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS | MGMT, MPG, UNG | ADORA2B 3863/4885GLA 1214/4885BLM 396/4885 |
| US-20210002286-A1 | IMIDAZOTETRAZINE COMPOUNDS | MCL1, IDH1, IDH2 | ADORA2B 3741/4885GLA 992/4885BLM 2535/4885 |
| US-20210315886-A1 | IMIDAZOTETRAZINE COMPOUNDS | MCL1, IDH1, IDH2 | ADORA2B 3741/4885GLA 992/4885BLM 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.